Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.
Read More from WSJ.com: US Business
Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug
Thursday, January 15